Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tiffany Piccari

Nurse Practitioner Canton, OH Nurse Practitioner

NPI 1316405707 CMS profile 10798323

1330 Mercy Dr Nw, Ste 520, Canton, OH 44708

Open in the dashboard

General payments

$2,699

80 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tiffany Piccari of Canton, OH is reported in the CMS Open Payments database as having received $2,699 across 80 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $558 4
2023 General $1,265 24
2022 General $56 3
2021 General $820 49

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tiffany Piccari
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Tiffany Piccari were reported at $558. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Tiffany Piccari Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $820 $135 $40–$426 $132
2022 $56 $152 $48–$470 $149
2023 $1,265 $166 $54–$529 $160
2024 $0 $173 $55–$556 $164
2025 $558 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $1,595 25 payments
  2. Amarin Pharma Inc. $174 11 payments
  3. Antares Pharma, Inc. $115 1 payment
  4. Pfizer Inc. $101 6 payments
  5. Endo Pharmaceuticals Inc. $97 1 payment
  6. Janssen Pharmaceuticals, Inc $86 5 payments
  7. AbbVie, Inc. $78 5 payments
  8. Novo Nordisk Inc $69 4 payments
  9. AstraZeneca Pharmaceuticals LP $66 4 payments
  10. Astellas Pharma US Inc $37 2 payments
  11. Other $281 16 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $1,363 66 payments
  2. Travel and Lodging $1,308 13 payments
  3. Education $27 1 payment
Products named General payments · program years 2021–2025
  1. INTERSTIM $1,595 25 payments
  2. Vascepa $174 11 payments
  3. XYOSTED $115 1 payment
  4. XIAFLEX $97 1 payment
  5. XARELTO $86 5 payments
  6. COLOGUARD DNA CAPTURE REAGENTS $78 5 payments
  7. RYBELSUS $69 4 payments
  8. Ozempic $69 4 payments
  9. FARXIGA $66 4 payments
  10. PREMARIN $49 3 payments
  11. Other $578 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,169

Median for Nurse Practitioner: 389

Drug cost

$147,391

Median for Nurse Practitioner: $21,885

Branded share of claims

37%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 188 $115,815
Gemtesa Vibegron Brand 21 $15,389
Tamsulosin Hcl Generic 381 $4,171
Estradiol Generic 26 $1,455
Oxybutynin Chloride Er Oxybutynin Chloride Brand 66 $1,372
Trimethoprim Generic 22 $1,092
Methenamine Hippurate Generic 19 $1,068
Tolterodine Tartrate Er Tolterodine Tartrate Brand 17 $948
Trospium Chloride Generic 19 $809
Fesoterodine Fumarate Er Fesoterodine Fumarate Brand 12 $743

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$22,213

Medicare's payments for the services billed

Medicare patients

246

Average age 75

Services billed

508

105 women, 141 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 58%
Chronic kidney disease 41%
Ischemic heart disease 37%
Diabetes 36%
Depression 36%
Heart failure 33%
Atrial fibrillation 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

80 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record